Evaluation and Treatment of Febrile Ulceronecrotic Mucha-Habermann Disease With Ruxolitinib and Tocilizumab as Guided by Cytokine Profile

JAMA Dermatol. 2021 Nov 1;157(11):1381-1383. doi: 10.1001/jamadermatol.2021.4047.

Richard Wu¹, Ashley DiLorenzo², Michael Lotke³, Kaiane Habeshian^{4

5}, Joel Brooks^{5

6}, Michael D Keller^{5

6}, A Yasmine Kirkorian^{4

5}

¹ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
² Department of Dermatology, MedStar Washington Hospital Center, Washington, DC.
³ Division of Hospitalist Medicine, Children's National Hospital, Washington, DC.
⁴ Division of Dermatology, Children's National Hospital, Washington, DC.
⁵ George Washington University School of Medicine & Health Sciences, Washington, DC.
⁶ Division of Allergy and Immunology, Children's National Hospital, Washington, DC.

No abstract available

MeSH terms